. 2022 Jul 8;19:100566. doi: 10.1016/j.iot.2022.100566

Table 11.

Alexa, has the COVID-19 vaccine been tested?

Original	Rephrased
Primary efficacy analysis demonstrates the Pfizer-Biotech vaccine to be 95 percent effective against COVID-19 beginning 28 days after the first dose; 170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group. The efficacy of the Moderna vaccine to prevent COVID-19 occurring at least 14 days after dose 2 was 94.5 percent.	Primary efficacy analysis demonstrates the Pfizer-Biotech vaccine to be 95 percent 5 percent ineffective against COVID-19 beginning 28 days after the first dose; 170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group contracted the virus. The inefficacy of the Moderna vaccine to prevent COVID-19 occurring at least 14 days after dose 2 was 94.5 percent 5.5 percent.

Original

Rephrased

Primary efficacy analysis demonstrates the Pfizer-Biotech vaccine to be 95 percent effective against COVID-19 beginning 28 days after the first dose; 170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group. The efficacy of the Moderna vaccine to prevent COVID-19 occurring at least 14 days after dose 2 was 94.5 percent.

Primary efficacy analysis demonstrates the Pfizer-Biotech vaccine to be 95 percent 5 percent ineffective against COVID-19 beginning 28 days after the first dose; 170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group contracted the virus. The inefficacy of the Moderna vaccine to prevent COVID-19 occurring at least 14 days after dose 2 was 94.5 percent 5.5 percent.